Recombinant HIV-1 Envelope Protein for Vaccine Use

In pursuit of an effective vaccine to end the global HIV-1/AIDS pandemic, researchers at the Vaccine Research Center (“VRC”) continue to study the structure of HIV-1. Recently, these researchers have determined the three-dimensional structure of the HIV-1 Envelope trimeric ectodomain (“Env”), comprised of three gp120 and three gp41 subunits, in its prefusion, mature, closed conformation.

The researchers hypothesize that immunization with the prefusion, closed HIV-1 Env protein will elicit a neutralizing immune response. The VRC researchers engineered a portion of the HIV-1 Env trimer to stabilize it in this closed conformation for use as an immunogen.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications:		Competitive Advantages:
Vaccine for prevention of HIV-1 infection. Therapeutic vaccine for treatment of HIV-1 infection.		Currently, no licensed HIV-1 vaccine exists.

Inventors:

Peter Kwong (NIAID)  ➽ more inventions...

Marie Pancera (NIAID)  ➽ more inventions...

Tongqing Zhou (NIAID)  ➽ more inventions...

Ivelin Georgiev (NIAID)  ➽ more inventions...

Michael Joyce (NIAID)  ➽ more inventions...

Priyamvada Acharya (NIAID)  ➽ more inventions...

Jason Gorman (NIAID)  ➽ more inventions...

Yongping Yang (NIAID)  ➽ more inventions...

Aliaksandr Druz (NIAID)  ➽ more inventions...

Guillaume Stewart-Jones (NIAID)  ➽ more inventions...

Rita Chen (NIAID)  ➽ more inventions...

Gwo-Yu Chuang (NIAID)  ➽ more inventions...

Ulrich Baxa (NIAID)  ➽ more inventions...

John Mascola (NIAID)  ➽ more inventions...

Rebecca Lynch (NIAID)  ➽ more inventions...

Baoshan Zhang (NIAID)  ➽ more inventions...

Cheng Cheng (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 10,400,015 issued 2019-09-03
US Application No. 62/136,480
PCT Application No. PCT/US2015/048729
US Application No. 15/508,885
US Application No. 16/557,894

Publications:
Pancera M, et al. PMID 25296255

Collaboration Opportunity:
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize HIV-1 immunogens for treating or preventing HIV-1 infection. For collaboration opportunities, please contact Dr. Barry Buchbinder, 240-627-3674; barry.buchbinder@nih.gov.


Licensing Contact:
Barry Buchbinder, Ph.D.
Email: BBuchbinder@niaid.nih.gov
Phone: 301-496-2644

OTT Reference No: E-178-2014-0
Updated: Oct 18, 2018